Doesn't history show us that Gilead will probably work out a deal with NICE for TAF regimes just like they came to an agreement with Sovaldi ?
I don't see TAF as being anything capable to drive Gilead's stock much higher, but it does provide some type of insurance for the future of their HIV market.
Market Data 
Markets 
AI
